What Hexarelin is
Hexarelin is a synthetic growth hormone secretagogue with ghrelin receptor activity and historical interest in endocrine and cardiovascular research.
Hexarelin is grouped under Fitness + Recovery on PeptideFactCheck because it is considered one of the stronger GH secretagogues in online peptide discussions.
The useful starting point is to separate the molecule itself from the internet story around it. It is usually brought up when people compare stronger versus cleaner GH-axis peptides.
Why people keep looking it up
People talk about hexarelin as a potent GH secretagogue.
Hexarelin activates ghrelin receptor pathways and has been studied for endocrine effects.
Hexarelin tends to stay in the conversation because it touches a familiar public theme: ghrelin receptor, gh secretagogue, and cardiac research. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Potency talk online should not be mistaken for proven practical benefit or long-term safety.
Human endocrine research exists, but practical optimization claims remain much less established.
Preclinical work has explored endocrine and tissue-specific effects.
Why this page carries the current tier: Human endocrine data is not the same as proven recovery, fat-loss, or longevity outcomes.
The current seed trail for Hexarelin is pulling from 1 literature source, 1 trials source, and 1 databases source.
Safety, limits, and regulatory context
Potency may also mean higher concern around endocrine effects and non-target outcomes.
No FDA-approved hexarelin drug product is listed in this V1 source trail.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Hexarelin. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Hexarelin is CID 6918297. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 6918297
- Formula
- C47H58N12O6
- Molecular weight
- 887.0
- InChIKey
- RVWNMGKSNGWLOL-GIIHNPQRSA-N
Matched synonyms include Hexarelin, Examorelin, 140703-51-1, EP-23905, examorelina, examoreline, L-Lysinamide, L-histidyl-2-methyl-D-tryptophyl-L-alanyl-L-tryptophyl-D-phenylalanyl-, MF-6003.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Hexarelin returns 0 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
No linked intervention records were returned by the current ClinicalTrials.gov query terms for this page.
Literature snapshot
The current PubMed query for Hexarelin returns 313 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.